Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.68 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.68 |
| ▸ | PKM | P14618 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9871166 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL186284 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL2142612 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL186818 | 0.98 | CYP4F2 (0.71) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL1661139 | 0.94 | CYP4F2 (0.65) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17756702 | 0.93 | CYP4F2 (0.60) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL17762731 | 0.92 | CYP4F2 (0.58) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL20597884 | 0.89 | CYP4F2 (0.59) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6257314 | 0.88 | CYP4F2 (0.85) | CYP4F2CYP4A11PKMTHRBHTT | |
| SCHEMBL6254544 | 0.88 | CYP4F2 (0.85) | CYP4F2CYP4A11PKMTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116410086-A | Method for preparing isobutyric acid derivative | 苏州特瑞药业股份有限公司 | 2023-07-11 | — | — | CN | claimed |
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2022-03-17 | — | — | US | claimed |
| EP-3906231-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | Lupin Limited (IN) | 2021-11-10 | — | — | EP | claimed |
| CN-113227061-A | Novel salts and polymorphs of bipedac acid | 印度鲁宾有限公司 | 2021-08-06 | — | — | CN | claimed |
| WO-2020141419-A2 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | LUPIN LIMITED (IN) | 2020-07-09 | — | — | WO | claimed |
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4695266-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-12-19 | — | — | US | disclosed |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | ESPERVITA THERAPEUTICS, INC. | 2024-12-05 | — | — | US | disclosed |
| WO-2024213143-A1 | SUBSTITUTED ALKANOIC-DIACIDS COMPOUND AND COMPOSITION AND USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| CN-113024467-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-08-06 | — | — | CN | disclosed |
| US-4794113-A | ANTICHOLESTEROL, ANTILIPEMIC, ANTICOAGULANT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1988-12-27 | — | — | US | disclosed |
| US-4758573-A | Heterocyclic group-containing compounds | G. D. SEARLE & CO. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0260613-A2 | Imidazopyridine derivatives, their preparation and their use as PAF-antagonists | G.D. Searle & Co. (US) | 1988-03-23 | — | — | EP | disclosed |
| EP-0254590-A2 | Aryl-di(thio)ether derivatives as antitumoral pharmaceutical compounds | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1988-01-27 | — | — | EP | disclosed |
| EP-0105575-B1 | 1-(1H-IMIDAZOLYL), 1-N-MORPHOLINYL AND PYRIDYL COMPOUNDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | G.D. Searle & Co. (US) | 1987-03-04 | — | — | EP | disclosed |
| US-4579862-A | TREATMENT OF CEREBROVASCULAR DISEACE, ISCHEMIA, DIABETES, ANGINA, MYOCARDIAL INFARCTION | G. D. SEARLE & CO. (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0130077-A2 | Phenoxy derivatives, their preparation, and pharmaceutical compositions containing them | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1985-01-02 | — | — | EP | disclosed |
| EP-0105575-A1 | 1-(1H-imidazolyl), 1-N-morpholinyl and pyridyl compounds, their preparation and pharmaceutical compositions containing them | G.D. Searle & Co. (US) | 1984-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12396972-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | CYP4F2 847/4885CYP4A11 552/4885PKM 1257/4885 |
| US-20220081385-A1 | NOVEL SALTS AND POLYMORPHIC FORM OF BEMPEDOIC ACID | HADH, ALDH5A1, ACAD9 | CYP4F2 184/4885CYP4A11 197/4885PKM 2411/4885 |
| US-20240398737-A1 | FUNCTIONALIZED LONG-CHAIN HYDROCARBON MONO- AND DI-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, AND THEIR USE FOR THE PREVENTION OR TREATMENT OF DISEASE | AHR, PKD1, CFTR | CYP4F2 847/4885CYP4A11 552/4885PKM 1257/4885 |
| US-20240417383-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | CYP4F2 2116/4885CYP4A11 735/4885PKM 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.